Drugs / EF-M2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07349420 | Jun → Oct 2025 | rheumatoid arthritis | S.LAB (SOLOWAYS) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EF-M2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07349420 ↗ |
| Known as | Immutalon | “EF-M2 (Immutalon) is an investigational product administered as a subcutaneous injection.” NCT07349420 ↗ |
| Route | Subcutaneous | “EF-M2 (Immutalon) is an investigational product administered as a subcutaneous injection.” NCT07349420 ↗ |